ArticleOncology letters2016
Molecular biology of gynecological cancer.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Breaking barriers in gynecologic malignancies with adoptive cell transfers and nanomedicine.Cell biomaterials · 2026Article
- Tumor versus Tumor Cell Targeting in Metal-Based Nanoparticles for Cancer Theranostics.International journal of molecular sciences · 2024Review
- Gynecologic Cancer, Cancer Stem Cells, and Possible Targeted Therapies.Frontiers in pharmacology · 2022Review
- LASSO and Bioinformatics Analysis in the Identification of Key Genes for Prognostic Genes of Gynecologic Cancer.Journal of personalized medicine · 2021Article
- p38β - MAPK11 and its role in female cancers.Journal of ovarian research · 2021Review
- Phytochemicals in Gynecological Cancer Prevention.International journal of molecular sciences · 2021Review
- The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer.International journal of molecular sciences · 2020Article
- Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2020Review
- Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a pathological condition in which the balance between cell growth and death is disordered. Various molecules have been reported to be involved in the oncogenic process of invasion, metastasis and resistance to treatment. An exponential growth in the collection of genomic and proteomic data in the past 20 years has provided major advances in understanding the molecular mechanisms of human cancer, which has been applied to diagnostic and treatment strategies. Targeted therapies have been developed and adopted, particularly for advanced, refractory or recurrent cancers, depending on individual molecular profiles. The aim of the present review is to provide a report of the current literature regarding the molecular biology of gynecological cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.